TVGN 960

TVGN 960 is an investigational, off-the-shelf, genetically unmodified T cell therapy being developed by Tevogen Bio for the treatment of HPV-related mouth and throat cancers. It utilizes CD8+ cytotoxic T lymphocytes to target virally induced neoplasms in the oral cavity and oropharynx. The therapy is part of Tevogen Bio’s ExacTcell platform, which aims to deliver precision immunotherapies for oncology and specialty care indications. As of early 2025, TVGN 960 remains in preclinical development[1][4][6]. The product is designed as an immune cell therapy (specifically a T cell-based modality) intended to address significant unmet needs in cancer care by harnessing the body’s own immune system without genetic modification[1][4][6].